This article is more than 5 years old. Information may no longer be current.
Children protected against PCV13 serotypes after introduction
Click Here to Manage Email Alerts
SAN FRANCISCO — From 2008 to 2011, there have been significant reductions in 19A and the 12 non-19A 13-valent pneumococcal conjugate vaccine serotypes in children aged 0 to 1 year, according to study findings presented at ID Week 2013.
Researchers evaluated age-specific proportions of invasive pneumococcal disease (IPD) caused by serotype 19A and other serotypes included in PCV13 (Prevnar 13, Pfizer) before (2008-2009) and after (2010-2011) introduction.
From 2008 to 2009, 37% of IPD cases in children aged 0 to 17 years were caused by serotype 19A, 37% in 2010 and 28% in 2011. Sixty-six percent of IPD cases were caused by the other 12 non-19A PCV13 serotypes from 2008 to 2009, 62% in 2010 and 48% in 2011.
However, researchers found that reductions were not consistent among the different age groups. There was a 44% reduction in the proportion of IPD caused by PCV13 serotypes in children aged 0 to 1 year compared with 17% in children aged 2 to 17 years. Among children aged 0 to 1 year, there was a 36% reduction of IPD caused by serotype 19A compared with no change among children aged 2 to 17 years. Twenty-seven percent of children younger than 1 year had a comorbid disease compared with 32% of children aged 1 to 2 years; 45% of children aged 3 to 5 years; and 60% of children aged 6 to 17 years.
“Children aged 2 to 17, however, had a reduction in non-19A PCV13 serotypes, but not 19A,” the researchers wrote. “Reasons for this could include lack of early indirect effect, virulence of 19A, and more comorbid disease and low PCV13 utilization in older children.”
For more information:
Mclaughlin JM. Abstract #443. Presented at: ID Week 2013; Oct. 2-6, 2013; San Francisco.
Disclosure: Some researchers report financial relationships with Pfizer.